- | Lumos Pharma
Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development
Lumos Pharma is dedicated to transforming the treatment landscape for rare pediatric diseases like PGHD. Lumos Pharma’s approach is not just about creating new drugs; it’s about rethinking the entire patient experience, prioritizing ease of use and minimizing the treatment burden on young patients and their families. Their work exemplifies a broader shift in the pharmaceutical industry towards patient-centric drug development — a paradigm that places the needs and well-being of patients at the forefront of every stage of the drug development process.
- | Addimmune
Overcoming Barriers to Adherence in HIV: A Case for an Innovative Approach to Treatment
Innovation in the HIV treatment landscape is playing a role in addressing medication adherence. In recent years, long-acting injectable antiretroviral monthly and bi-monthly treatment options have been approved – a welcome alternative for people living with HIV. We are now on the cusp of it coming full circle from the days when patients took multiple pills a day to potentially a one-and-done single-dose treatment
- | Elicio Therapeutics
Elicio Therapeutics Begins Phase II Cancer Vaccine Trial in KRAS-Mutant Pancreatic Cancer
Elicio Therapeutics on Thursday began treating patients with KRAS-mutant pancreatic ductal carcinoma in the Phase II portion of the AMPLIFY-7P trial in which it is testing the cancer vaccine ELI-002 7P as an adjuvant treatment.
- | Recce Pharmaceuticals
Revolutionary Antibiotic-Resistant Gonorrhea Treatment: A Possible Breakthrough with Recce 327
With gonorrhea’s rising antibiotic resistance, Recce 327 by Recce Pharmaceuticals emerges as a game-changer, showing 99% efficacy in preclinical trials and promising potential against antibiotic-resistant bacteria globally.
- | Life Biosciences
The science of ageing and restoring healthspan
Life Biosciences are specifically focused on restoring and prolonging one’s healthspan by targeting the underlying biology of ageing.
- | MeiraGTx
MeiraGTx gifts remaining gene therapy rights to J&J for up to $415M
MeiraGTx has handed off the remaining interests for a rare disease gene therapy to Johnson & Johnson in a deal that could reach $415 million.
- | Anima Biotech
The future of mRNA biology and AI convergence
In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process.
- | MeiraGTx
MeiraGTx gifts remaining gene therapy rights to J&J for up to $415M
MeiraGTx has handed off the remaining interests for a rare disease gene therapy to Johnson & Johnson in a deal that could reach $415 million.
